Pacira Pharm Inc (PCRX) 39.04 $PCRX Array (ARRY
Post# of 273257
Posted On: 09/04/2016 5:15:25 AM
Pacira Pharm Inc (PCRX) 39.04 $PCRX
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), ARRY: 3.50 (-0.02), NVS: 79.38 (+1.11)
Roche Immuno-oncology Drug Tecentriq Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:22AM CDT
Roche (RHHBY) announced positive results from a phase III study, OAK, on its immuno-oncology drug, Tecentriq.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 39.04 (-1.33)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.86 (-0.06), VRX: 28.76 (-0.36), ANIP: 59.86 (-1.56), PCRX: 39.04 (-1.33)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
Roche Gets FDA Nod for Emergency Use of Zika Virus Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:41AM CDT
Roche Holdings (RHHBY) announced that the FDA has issued an Emergency Use Authorization (EUA) for its LightMix Zika rRT-PCR Test.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Novartis (NVS) Reports Positive Phase III Results on MS Drug
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:20AM CDT
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
TEVA: 51.22 (+0.32), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), NVS: 79.38 (+1.11)
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 72.42 (-3.17), MDCO: 38.31 (-0.66), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 235.96 (-1.80), CEMP: 22.11 (-0.18), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:50AM CDT
Novartis AG (NVS) entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti-PCSK9 antibody, LGT-209.
XNCR: 20.35 (-1.08), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), NVS: 79.38 (+1.11)
Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 13.26 (-0.09), MDCO: 38.31 (-0.66), CBYL: 0.49 (+0.01), PCRX: 39.04 (-1.33)
Roche Launches Accu-Chek Blood Glucose Monitoring System
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:47AM CDT
The launch of new systems will help Roche (RHHBY) offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:52AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
ANIP: 59.86 (-1.56), SUPN: 21.97 (-0.06), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.63 (+0.27), GWPH: 82.73 (+0.45), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Valeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:21AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received the requisite lender approval for an amendment to its credit facility which is scheduled to close next week.
VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Think Out of the Box: Bet on 6 Stocks with Rising P/E
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:09AM CDT
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
ANW: 10.29 (+0.10), MPAA: 29.06 (+0.39), STMP: 99.61 (+0.76), DXYN: 4.68 (-0.16), PCRX: 39.04 (-1.33), HUM: 177.33 (+0.80)
OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:57AM CDT
Shares of OncoGenex Pharmaceuticals, Inc. (OGXI) were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer.
OGXI: 0.53 (-0.02), ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 19.82 (-0.41), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 10:08AM CDT
Shares of Aurinia Pharmaceuticals Inc. (AUPH) crashed 55% after the company reported mixed results from a phase IIb study, AURA-LV, on its pipeline candidate, voclosporin.
AUPH: 2.05 (+0.10), ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), ARRY: 3.50 (-0.02), NVS: 79.38 (+1.11)
Roche Immuno-oncology Drug Tecentriq Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:22AM CDT
Roche (RHHBY) announced positive results from a phase III study, OAK, on its immuno-oncology drug, Tecentriq.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company. PCRX: 39.04 (-1.33)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.86 (-0.06), VRX: 28.76 (-0.36), ANIP: 59.86 (-1.56), PCRX: 39.04 (-1.33)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
Roche Gets FDA Nod for Emergency Use of Zika Virus Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:41AM CDT
Roche Holdings (RHHBY) announced that the FDA has issued an Emergency Use Authorization (EUA) for its LightMix Zika rRT-PCR Test.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Novartis (NVS) Reports Positive Phase III Results on MS Drug
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:20AM CDT
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
TEVA: 51.22 (+0.32), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), NVS: 79.38 (+1.11)
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 72.42 (-3.17), MDCO: 38.31 (-0.66), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 235.96 (-1.80), CEMP: 22.11 (-0.18), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:50AM CDT
Novartis AG (NVS) entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti-PCSK9 antibody, LGT-209.
XNCR: 20.35 (-1.08), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), NVS: 79.38 (+1.11)
Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 13.26 (-0.09), MDCO: 38.31 (-0.66), CBYL: 0.49 (+0.01), PCRX: 39.04 (-1.33)
Roche Launches Accu-Chek Blood Glucose Monitoring System
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:47AM CDT
The launch of new systems will help Roche (RHHBY) offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:52AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
ANIP: 59.86 (-1.56), SUPN: 21.97 (-0.06), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.63 (+0.27), GWPH: 82.73 (+0.45), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Valeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:21AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received the requisite lender approval for an amendment to its credit facility which is scheduled to close next week.
VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Think Out of the Box: Bet on 6 Stocks with Rising P/E
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:09AM CDT
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
ANW: 10.29 (+0.10), MPAA: 29.06 (+0.39), STMP: 99.61 (+0.76), DXYN: 4.68 (-0.16), PCRX: 39.04 (-1.33), HUM: 177.33 (+0.80)
OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:57AM CDT
Shares of OncoGenex Pharmaceuticals, Inc. (OGXI) were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer.
OGXI: 0.53 (-0.02), ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 19.82 (-0.41), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 10:08AM CDT
Shares of Aurinia Pharmaceuticals Inc. (AUPH) crashed 55% after the company reported mixed results from a phase IIb study, AURA-LV, on its pipeline candidate, voclosporin.
AUPH: 2.05 (+0.10), ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
(0)
(0)Scroll down for more posts ▼